Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2025-12-26 @ 5:14 PM
Study NCT ID:
NCT06561360
Status:
RECRUITING
Last Update Posted:
2025-10-07
First Post:
2024-08-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-09-09
Start Date Type:
ACTUAL
Primary Completion Date:
2027-09-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-09-09
Completion Date Type:
ESTIMATED
First Submit Date:
2024-08-13
First Submit QC Date:
None
Study First Post Date:
2024-08-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-01
Last Update Post Date:
2025-10-07
Last Update Post Date Type:
ESTIMATED